• Thu Sep 14 2023

    Meet us at LSX Nordic and BioFIT this fall

    Sarsia Partner Farzad Abdi-Dezfuli will participate in two high-level biotech pa

    Read full article
  • Mon May 08 2023

    Henrik Solberg-Johansen joins the Sarsia team

    Henrik Solberg-Johansen joined the Sarsia team on May 1st.

    Read full article
  • Mon May 08 2023

    Arxx Therapeutics initiates first-in-human trial

    Arxx Therapeutics initiates first-in-human trial of AX-202 – a monoclonal antibody under development for fibrotic diseases

    Read full article
  • Wed Apr 26 2023

    Sveinung Hole to become new CEO in Sarsia

    Sarsia Management AS announced today that Sveinung Hole has been appointed as Ma

    Read full article
  • Tue Mar 07 2023

    OculAudio signs deal with hearing implant giant

    OculAudio ® Corti AS today announced that it has entered of a collaborative rese

    Read full article
  • Mon Jan 02 2023

    Coegin Pharma raises 25 mSEK

    Coegin Pharma AB (COEGIN:Nordic GM) raises 25,3 mSEK through combined rights issue and directed new issue

    Read full article
  • Fri Dec 16 2022

    Rallybio publishes promising results with technology aquired from Prophylix Pharma

    American biotech company Rallybio publishes proof-of-concept data from animal studies with technology aquired from Tromsø-based Prophylix Pharma

    Read full article
  • Tue Dec 06 2022

    Nykode Therapeutics announces clinical collaboration with MSD

    Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.1

    Read full article
  • Wed Nov 23 2022

    Heimdall Power partners with Lede to enable green hydrogen production

    Heimdall Power announces that they have just signed a contract with the Norwegia

    Read full article
  • Fri Mar 04 2022

    Coegin Pharma merges with Follicum

    Coegin Pharma has announced successfully completing the merger acquisition of Lund-based diabetes company Follicum.

    Read full article
  • Thu Jul 08 2021

    Bergenbio receives FDA fast track designation for bemcentinib

    Read full article
  • Tue May 18 2021

    APIM Therapeutics completes private placement and enters phase-2

    APIM Therapeutics today announces the completion of a private placement directed towards existing and certain new investors in the Company. The procee

    Read full article

Read more about our work

  • Approach

    Reliability is at the core of what we do

    Visit page
  • Life Sciences

    We invest in a healthier future

    Visit page
  • Technology, Energy and Sustainability

    We are conscious of our responsibility

    Visit page